Evidence map›Paper›PMID 31129802›Full record

ArticleInternational journal of hematology2019

Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.

Kanae Sakakibara, Takayuki Tsujioka, Jun-Ichiro Kida, Nami Kurozumi, Takako Nakahara, Shin-Ichiro Suemori, Akira Kitanaka, Yujiro Arao, Kaoru Tohyama

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kanae SakakibaraDivision of Medical Technology, Kawasaki University of Medical Welfare, Okayama, 701-0192, Japan.
Takayuki TsujiokaDepartment of Laboratory Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan.
Jun-Ichiro KidaDepartment of Laboratory Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan.
Nami KurozumiDivision of Medical Technology, Kawasaki University of Medical Welfare, Okayama, 701-0192, Japan.
Takako NakaharaDivision of Medical Technology, Kawasaki University of Medical Welfare, Okayama, 701-0192, Japan.
Shin-Ichiro SuemoriDepartment of Laboratory Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan.
Akira KitanakaDivision of Medical Technology, Kawasaki University of Medical Welfare, Okayama, 701-0192, Japan.
Yujiro AraoField of Medical Technology, Graduate School of Health Sciences, Okayama University, Okayama, 700-8558, Japan.
Kaoru TohyamaDivision of Medical Technology, Kawasaki University of Medical Welfare, Okayama, 701-0192, Japan. ktohyama@med.kawasaki-m.ac.jp.ORCID http://orcid.org/0000-0002-0812-9816
Kawasaki Medical School · JPOkayama University · JPKawasaki University of Medical Welfare · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A MEK1/2 inhibitor, binimetinib is promising as a therapeutic agent for malignant melanoma with N-RAS mutation. We examined in vitro effects of binimetinib on 10 human myeloid/lymphoid leukemia cell lines, and found that three of five cell lines with N-RAS mutation and one of five without N-RAS mutation were responsive to treatment with binimetinib. Binimetinib inhibited cell growth mainly by inducing G

Indexed as

Genes, rasAminopyridinesAntineoplastic AgentsApoptosisBenzimidazolesCell CycleCell Line, TumorDNA, NeoplasmDrug Resistance, NeoplasmDrug Screening Assays, AntitumorG1 PhaseGene Expression Regulation, LeukemicHumansLeukemiaMAP Kinase Signaling SystemMorpholinesAminopyridinesAntineoplastic AgentsBenzimidazolesbinimetinibDNA, NeoplasmMorpholinesNeoplasm ProteinsNVP-BKM120Oncogene Protein p21(ras)Phosphatidylinositol 3-KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktAkt phosphorylationG1 arrestMyelodysplastic syndromes (MDS)N-RAS mutation

Identifiers

PMID31129802
OpenAlexW2946705682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.